Roselle De Guzman, MD, of the Manila Central University-FDTMF Hospital, joined Lung Cancers Today at the IASLC 2024 World Conference on Lung Cancer to discuss her plenary presentation titled “Unmasking Indoor Pollutants and Lung Cancer Risk.”
Advertisement
Using a telephone strategy improved HIV testing rates among US Veterans.
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Researchers estimated hyperkalemia incidence in patients with chronic kidney disease from routine clinical care.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
While biliary tract cancer is one of the fastest-growing types of early-onset cancers, little is known about its biology.
The Latest From Heme Today
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.
A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.
A recent study brings insight regarding the best timing for this CAR-T therapy in patients with prior BCMA-directed therapy.
Dr. Theodore Wun and Dr. Olubusola Oluwole investigated the causes of rising stroke rates among pediatric and adult patients.
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.